MX2023007801A - Células t diseñadas. - Google Patents
Células t diseñadas.Info
- Publication number
- MX2023007801A MX2023007801A MX2023007801A MX2023007801A MX2023007801A MX 2023007801 A MX2023007801 A MX 2023007801A MX 2023007801 A MX2023007801 A MX 2023007801A MX 2023007801 A MX2023007801 A MX 2023007801A MX 2023007801 A MX2023007801 A MX 2023007801A
- Authority
- MX
- Mexico
- Prior art keywords
- engineered
- cells
- knockdown
- modification
- nucleic acid
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 102100037850 Interferon gamma Human genes 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/53—CD2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
La presente descripción se refiere a las células T diseñadas para comprender una modificación, p. ej., inactivación, de una secuencia de ácido nucleico endógeno que codifica un IFNG, una modificación, p. ej., inactivación, de una secuencia de ácido nucleico endógeno que codifica un TNFA, y la inserción de una o más secuencias que codifican una molécula promotora de células T reguladoras y composiciones y usos de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063131987P | 2020-12-30 | 2020-12-30 | |
PCT/US2021/065524 WO2022147133A1 (en) | 2020-12-30 | 2021-12-29 | Engineered t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007801A true MX2023007801A (es) | 2023-08-21 |
Family
ID=80050925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007801A MX2023007801A (es) | 2020-12-30 | 2021-12-29 | Células t diseñadas. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4271799A1 (es) |
JP (1) | JP2024502036A (es) |
KR (1) | KR20230153356A (es) |
CN (1) | CN116848235A (es) |
AU (1) | AU2021411521A1 (es) |
CA (1) | CA3206484A1 (es) |
IL (1) | IL304069A (es) |
MX (1) | MX2023007801A (es) |
TW (1) | TW202235615A (es) |
WO (1) | WO2022147133A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024006955A1 (en) * | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | METHODS FOR PRODUCING ZINC FINGER NUCLEASES HAVING MODIFIED ACTIVITY |
DK3401400T3 (da) | 2012-05-25 | 2019-06-03 | Univ California | Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering |
CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
CN110643600A (zh) | 2012-10-23 | 2020-01-03 | 基因工具股份有限公司 | 用于切割靶dna的系统及其用途 |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
EA030650B1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
US20150376587A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
JP6778175B2 (ja) | 2014-07-16 | 2020-10-28 | ノバルティス アーゲー | 脂質ナノ粒子ホスト中に核酸を封入する方法 |
US9963710B2 (en) | 2014-12-23 | 2018-05-08 | Syngenta Participations Ag | Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications |
CA2978314A1 (en) | 2015-03-03 | 2016-09-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
WO2017004279A2 (en) | 2015-06-29 | 2017-01-05 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
CN110291198A (zh) | 2016-12-08 | 2019-09-27 | 因特利亚治疗公司 | 经修饰的指导rna |
CA3062698A1 (en) | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
IL311278A (en) | 2017-09-29 | 2024-05-01 | Intellia Therapeutics Inc | Polynucleotides, preparations, and methods for genome editing |
WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
WO2019178259A2 (en) * | 2018-03-14 | 2019-09-19 | Celledit Llc | Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy |
CN118325839A (zh) | 2018-03-27 | 2024-07-12 | 宾夕法尼亚大学董事会 | 具有增强功能的修饰的免疫细胞及其筛选方法 |
EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
BR112021007025A2 (pt) | 2018-10-16 | 2021-08-03 | Intellia Therapeutics, Inc. | composições e métodos para imunoterapia |
WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
US20220273712A1 (en) * | 2019-06-07 | 2022-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Foxp3 engineered cd4+ t cells for use in treg-based immunotherapy |
-
2021
- 2021-12-29 AU AU2021411521A patent/AU2021411521A1/en active Pending
- 2021-12-29 WO PCT/US2021/065524 patent/WO2022147133A1/en active Application Filing
- 2021-12-29 CN CN202180093689.5A patent/CN116848235A/zh active Pending
- 2021-12-29 KR KR1020237025734A patent/KR20230153356A/ko unknown
- 2021-12-29 JP JP2023539978A patent/JP2024502036A/ja active Pending
- 2021-12-29 MX MX2023007801A patent/MX2023007801A/es unknown
- 2021-12-29 TW TW110149370A patent/TW202235615A/zh unknown
- 2021-12-29 CA CA3206484A patent/CA3206484A1/en active Pending
- 2021-12-29 IL IL304069A patent/IL304069A/en unknown
- 2021-12-29 EP EP21848454.1A patent/EP4271799A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL304069A (en) | 2023-08-01 |
CA3206484A1 (en) | 2022-07-07 |
AU2021411521A1 (en) | 2023-08-03 |
EP4271799A1 (en) | 2023-11-08 |
JP2024502036A (ja) | 2024-01-17 |
KR20230153356A (ko) | 2023-11-06 |
CN116848235A (zh) | 2023-10-03 |
WO2022147133A1 (en) | 2022-07-07 |
TW202235615A (zh) | 2022-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2569733A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
WO2022067130A3 (en) | Prime editing guide rnas, compositions thereof, and methods of using the same | |
WO2008109837A3 (en) | Method for expression of small antiviral rna molecules with reduced cytotoxicity within a cell | |
MX339632B (es) | Metodo para producir adamts13 recombinante en cultivo celular. | |
WO2018097540A3 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
BRPI0714495B8 (pt) | lentivírus deficiente para replicação recombinante pseudotipado | |
IN2012DN00403A (es) | ||
ATE549395T1 (de) | Medium und kultur von embryonalen stammzellen | |
MX2023007801A (es) | Células t diseñadas. | |
MX2022002462A (es) | Composiciones y métodos para la modificación de cll1. | |
MX2014009306A (es) | Metodo sin alimentadoras para cultivo de celulas madre espermatogonias de bovino y porcino. | |
WO2022221359A8 (en) | Epstein-barr virus mrna vaccines | |
MX2022001255A (es) | Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales. | |
MX2020005724A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX2021014306A (es) | Composiciones y métodos para la modificación de cd33. | |
CR20220425A (es) | COMPOSICIONES Y MÉTODOS PARA INCREMENTAR LA VIDA UTIL DEL BANANO (Divisional 2019-0575) | |
WO2013019857A3 (en) | Method for improving the success rate of hematopoietic stem cell transplants | |
MX2023002246A (es) | Sistema sintetico de crispr-cas en miniatura (casmini) para modificacion de genomas de eucariotas. | |
MX2022005327A (es) | Tintes y composiciones que contienen ciclooctatetraeno.. | |
MX2021012158A (es) | Métodos para la integración de una secuencia de adn donante en el genoma de bacillus usando constructos de adn recombinante lineal y composiciones de los mismos. | |
MX2022000425A (es) | Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras. | |
MX2010005094A (es) | Complejo de acido nucleico y composicion de suministro de acido nucleico. | |
MX2022010280A (es) | Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias. | |
MX2021003995A (es) | Plasmido que contiene una secuencia que codifica un arnm con una cola de poli(a) segmentada. |